yes, not much new but here is some of what I heard:
Focused on excitement of NSCLC data and how this trial is believed (internally at ARQL and with external thought leaders) to be a strong efficacy signal of activity. Pointed to ASCO for more details. There may or may not be overall survival data presented there since currently there has not been enough events in the trial to determine this. They are exploring several paths for ph3 trial, but would like to learn more from NSCLC trial (including survival trend) and other ARQ 197 trials to determine this path. Mentioned the importance of the control arm performing similiarly to historical data which it appears to do.
Several of the phase 2 trials have a randomized design and therefor have a good opportunity for positive signals will be the HCC trial with sorafenib reporting next year and the CRC trial with chemo the year after that. Some other single arm trials in smaller tumor types that can also be meaninful (germ cell tumors seemed to be a focus here).
Talked about younger pipeline and how FGF and RAF inhibitor programs have progressed faster than he had expected. Mentions this validates their discovery model and puts them in a good position of having choices moving forward (referenced position of many companies that have difficulty identifying a second candidate beyond their lead compound).
There was no mention of the shelf filed yesterday.
Generally acknowledged that they've been receiving a lot of attention with lung data and ASCO presentation with c-met inhibitor, also mentioned something like 4 additional posters will be presented at the meeting.
Not sure why the selling is going on now, but I assume its related to concern with the shelf and also the lack of eyeballs on the stock now. I still believe strongly that ARQL will find a lot of new investor money around ASCO. I actually sold my position (around 6) today not because of what I heard but just because of general weakness in the stock price and technicals. I will get back in for sure in the next couple of weeks its just a matter of where (pullback could be a good opportunity ultimately).